PBM Revenues Offer Boost to Major Insurers in Third Quarter

Large insurer-affiliated PBMs saw strong results for the third quarter of 2020, in several cases driving revenues for parent companies that are grappling with various disruptive effects of the coronavirus pandemic.

In earnings conference calls over the last month, company executives from CVS Health Corp., Cigna Corp. and Anthem, Inc., generally touted performance from their PBMs. Both Cigna and CVS credited their PBM business segments with driving strong third-quarter earnings for their companies. UnitedHealth Group, however, reported a 2% year-over-year decline in PBM earnings, which the company attributed to a pandemic-related drop-off in prescription volume.

© 2024 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

pills-and-cash
May 9

Specialty Drug Benefits Survey Spotlights Gene Therapy, Biosimilar Strategies

READ MORE
executives-and-chart
May 9

PBMs’ 1Q Earnings Calls Are All About Biosimilar, GLP-1 Programs

READ MORE
pills-and-bottles
May 9

High Price Tag, Accelerated Approval for New NASH Drug May Give Payers Pause

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today